Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Operating Leases (2023 - 2025)

Monte Rosa Therapeutics' Operating Leases history spans 3 years, with the latest figure at $34.8 million for Q4 2025.

  • For Q4 2025, Operating Leases fell 10.79% year-over-year to $34.8 million; the TTM value through Dec 2025 reached $34.8 million, down 10.79%, while the annual FY2025 figure was $34.8 million, 10.79% down from the prior year.
  • Operating Leases reached $34.8 million in Q4 2025 per GLUE's latest filing, down from $35.9 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $44.4 million in Q2 2023 to a low of $34.8 million in Q4 2025.
  • Average Operating Leases over 3 years is $40.1 million, with a median of $40.5 million recorded in 2024.
  • Peak YoY movement for Operating Leases: fell 3.32% in 2024, then fell 10.79% in 2025.
  • A 3-year view of Operating Leases shows it stood at $42.9 million in 2023, then fell by 9.04% to $39.0 million in 2024, then dropped by 10.79% to $34.8 million in 2025.
  • Per Business Quant, the three most recent readings for GLUE's Operating Leases are $34.8 million (Q4 2025), $35.9 million (Q3 2025), and $37.0 million (Q2 2025).